FDA: Gilead rep made misleading statements
Pharma Compliance Alert, March 18, 2009
A Gilead Sciences representative made false or misleading statements about the company’s Letairis drug, according to an FDA warning letter.
A Gilead representative minimized the risks associated with the use of Letairis during the 2008 Pulmonary Hypertension Association International Pulmonary Hypertension Conference and Scientific Sessions in Houston, TX, by misleadingly suggesting that the risks associated with the drug’s risk management plan do not apply to Letairis, the FDA said. As a result of the promotional activity, the drug is misbranded under the Food, Drug, and Cosmetic Act.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched